All In Biotech

Drug Trial Radar · NCT00224055

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Mar 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Apr 2003

Primary completion

Sep 2004

Study completion Sep 2004

Sponsor

Lead sponsor
Watson PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).

Conditions

  • Anemia, Iron-Deficiency
  • Kidney Failure, Chronic

Interventions

  • Sodium Ferric Gluconate Complex in Sucrose InjectionDrug

    Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks

  • Ferrous sulfate tabletsDrug

    ferrous sulfate, 325 mg oral, three times daily for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin (Hgb)Time frame: Baseline to 10 weeks

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    San Diego, California

  • Site not named

    Hines, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Birmingham, New York

  • Site not named

    Mineola, New York

  • Site not named

    New York, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Charlotte, South Carolina

  • Site not named

    Chattanooga, Tennessee

  • Site not named

    Memphis, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Fairfax, Virginia

  • Site not named

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.